CSL stock rallied 5% to A$165.88 on Wednesday, hitting a level not seen in more than six months as investors reacted to the companys full-year results and a substantial buyback plan. The upside extended a move that began the previous session, after the biopharmaceutical company reported FY26 results and announced an on-market share repurchase program of A$1.1 billion.
Management said the firms multi-year earnings reset has reached a floor and laid out a path back to growth. CSL guided to approximately 5% growth in underlying net profit after tax for FY27 at constant currency, a projection well ahead of the roughly 2% consensus that analysts had been modelling. The stronger-than-expected guidance and the buyback together supported investor confidence and were cited as core drivers for continued accumulation into Wednesday's trading.
The reported underlying FY26 metrics were modest but sufficient to clear analyst forecasts. Total revenue was reported at US$15.8 billion, down 1% year-on-year. Underlying NPATA was US$3.1 billion, a 2% decline that nevertheless slightly beat expectations. While these underlying figures were not dramatic, they met the bar market participants had set for the period.
On a statutory basis, CSL posted a net loss of US$2.6 billion. That loss was driven by US$7.1 billion in pre-tax impairments, primarily associated with the CSL Vifor acquisition and assets that the company identified as under-utilised. Market reaction treated those impairments as known and non-recurring items rather than as evidence of ongoing operational deterioration. Crucially for analysts, the company did not issue any further guidance cut alongside the results, a threshold that observers said was the most important requirement for the report to satisfy.
Beyond the headline numbers, a separate supply agreement between Haemonetics and CSL Plasma for NexSys PCS plasma collection devices was noted as an additional but smaller positive signal for the firms plasma collection network.
CSL's share performance contrasted with broader market moves, with the stock rising despite a 0.3% drop in the ASX 200 index during the same period. The combination of clearer growth guidance, a large buyback, and the treatment of impairments as one-off items underpinned the stock's renewed strength.
Key points
- CSL stock rose 5% to A$165.88, reaching a six-plus month high following FY26 results and a A$1.1 billion buyback announcement.
- Management guided to about 5% underlying net profit after tax growth for FY27 at constant currency, above the roughly 2% consensus.
- Underlying FY26: revenue US$15.8 billion (down 1%); underlying NPATA US$3.1 billion (down 2% but slightly ahead of estimates). Sectors impacted include biotech, pharmaceuticals, and Australian equity markets.
Risks and uncertainties
- The statutory net loss of US$2.6 billion driven by US$7.1 billion in pre-tax impairments tied to the CSL Vifor acquisition and under-utilised assets represents a material charge that affected reported earnings; the market treated these as non-recurring but they remain a notable accounting headwind.
- Underlying performance was modest, not spectacular, which leaves execution risk if underlying sales and margins do not improve as management expects; this affects investor sentiment in biotech and pharmaceutical equities.
- The supply agreement between Haemonetics and CSL Plasma was described as a minor positive; reliance on incremental operational improvements introduces uncertainty for the plasma collection network's contribution to growth.